MCL-135 BRUIN MCL-321, a Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated, BTK Inhibitor Naïve Mantle Cell Lymphoma (Trial in Progress)

Autor:	Ito, Rodrigo 1, Eyre, Toby A. 2, Shah, Nirav N. 3, Gouill, Steven Le 4, Dreyling, Martin 5, Vandenberghe, Elisabeth 6, Jurczak, Wojciech 7, Wang, Yucai 8, Cheah, Chan Y. 9, Gandhi, Mitul 10, Chay, Christopher 11, Sharman, Jeff 12, Andorsky, David J. 13, Song, Yuqin 14, Stark, Amy 1, Muthig, Valerie 1, Wang, Michael L. 15
Zdroj:	In Clinical Lymphoma, Myeloma and Leukemia October 2022 22 Supplement 2:S395-S396
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect